Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
Patients with resected or irradiated brain metastases or those treated with stereotactic radiation therapy are eligible to enroll, provided that they do not require treatment with steroids that exceeds 10 mg of prednisone daily or equivalent
Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate, or extracorporeal photopheresis
Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids > 20 mg of prednisone (or equivalent) once daily (QD)
Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310
Ongoing chronic systemic steroid therapy required (>10 mg oral prednisone daily or equivalent)
Physiologic doses of corticosteroids are permitted (i.e., no more than 10 mg of prednisone daily)
Patients requiring chronic high dose immunosuppressants including steroids (prednisone daily equivalent of >= 10 mg)
Daily requirement for corticosteroids (> 10 mg prednisone once daily [QD] or equivalent)
Any chronic medical condition requiring a higher dose of corticosteroid than equivalent of 5 mg prednisone/prednisolone once daily
No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomization
Patient receives chronic steroid use > 10 mg prednisone (or steroid equivalent) daily
Concomitant corticosteroids unless patient has been on a stable dose of prednisone (or equivalent) of =< 10 mg daily for at least 2 weeks prior to first dose of study drug
Receiving steroids > the equivalent of 10 mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis
Must be on =< 20 mg of oral daily prednisone or equivalent for GVHD
Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment
Pre-existing condition that warrants long-term corticosteroid use in excess of 10 mg prednisone/prednisolone daily. (Note: If a subject has been receiving glucocorticoids other than prednisone or prednisolone, it will be necessary to switch the glucocorticoids to prednisone or prednisolone 5 mg twice daily prior to day 1)
Steroid doses greater than an equivalent of prednisone 10 mg daily
Subject is receiving systemic steroids at doses greater than the equivalent of prednisone 10 mg daily, with the exception of intermittent use for the treatment of emesis
Receiving systemic steroid therapy of > 10 mg prednisone daily or equivalent\r\n* Note:\r\n** Corticosteroid use on study after cycle 1 for management of adverse events, serious adverse events, and events of clinical interest, as a premedication for IV contrast allergies/reactions, or if considered necessary for a subject’s welfare is\r\nallowed\r\n** Subjects who receive daily steroid replacement therapy are an exception; daily prednisone at doses of 5 to 7.5 mg is an example of replacement therapy\r\n** Equivalent hydrocortisone doses are also permitted if administered as replacement therapy
Requirement for corticosteroids greater than the equivalent of 10 mg of prednisone daily for more than 2 weeks.
Medical history of autoimmune disease (e.g. Crohn’s disease, ulcerative colitis) or other disease requiring systemic glucocorticoid or immunosuppressive therapy; subjects who receive daily steroid replacement therapy serve as an exception to this rule; daily prednisone equivalent at doses up to 10 mg would qualify
Concurrent immunosuppressive therapy. A stable dose of prednisone <10 mg daily or inhaled corticosteroids are allowed.
Long term or concurrent use of corticosteroid therapy other than for premedication or supportive care use as detailed in the protocol; physiologic doses of steroids (e.g. equivalent to or less than oral prednisone 10 mg daily) are allowed and do not require approval
Patients who are on high dose steroid (e.g. > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)
Patients with treated supratentorial metastases are allowed if stable, the patient is off steroids or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent) and no evidence of intracranial hemorrhage
Receiving corticosteroids at > 20 mg (age > 17) or > 0.5 mg/kg (age < 18) daily prednisone dose or equivalent.
At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted).
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810
Patients requiring chronic systemic immunosuppressants, including steroids (prednisone daily equivalent of >10 mg).
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of BI 754091
Ongoing glucocorticoids (prednisone > 10 mg daily, or equivalent); higher doses (> 10 mg daily) are permitted for up to 5 days to help control disease related symptoms
Patients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy as defined no greater than 20 mg of prednisone daily) within 1 week before administration of the first dose of study drug
Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone daily; use of inhaled, intranasal, intra-articular and topical steroids is acceptable, as is a short course (i.e. =< 1 day) of corticosteroids to prevent a reaction to the IV contrast used for CT scans
Had treatment with a short course of corticosteroids (> 10mg daily prednisone equivalents) for symptom relief within 1-week prior to screening.
Patients who have received prior immunotherapy whose side effects have resulted in a requirement of immunosuppressive medications (> 10 mg of prednisone daily or equivalent daily steroid daily, or infliximab, cyclosporine or equivalent immunosuppressive medication) or who have other autoimmune conditions that require immunosuppressive medications as above at the time of screening are excluded
No prior treatment except a prior limited-field radiotherapy, a short course of glucocorticoids =< 25 mg daily of prednisone equivalent which must cease prior to day 1 of cycle 1, and/or cyclophosphamide for an urgent lymphoma related problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome)
Patients who require emergent use of systemic steroids, chronic use of prednisone (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or radiotherapy.
Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).
Patients who are on high dose steroid (e.g. > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)
The subject can be on one or more of the following: prednisone (or equivalent corticosteroid) dose =< 20 mg, daily mycophenolate mofetil dose =< 2000 mg/d and cyclosporine/tacrolimus at =< therapeutic blood trough levels; the doses listed are the highest allowed for eligibility
Myelofibrosis subjects must have been treated with ruxolitinib for ? 6 months with a stable dose for ? 8 weeks (acceptable doses are 5 mg twice daily [BID] to 25 mg BID).
No chronic systemic corticosteroids (defined as the equivalent of prednisone >= 20 mg orally [PO] daily for > 6 months during the past year)
Immunosuppressive or systemic hormonal therapy (> 10 mg daily prednisone equivalent) within 2 weeks prior to first administration of IMP and during study; allowed therapies are specified in the protocol.
Medical condition requiring any form of chronic systemic immunosuppressive therapy (steroid or other) except physiologic replacement doses of hydrocortisone or equivalent (no more than 30 mg hydrocortisone or 10 mg prednisone equivalent daily) for < 30 days duration.
Patients requiring corticosteroids use at doses greater than prednisone 10 mg daily equivalent (use of inhaled steroids, and short-term steroid for radiologic contrast allergy, or treatment of immune-related adverse events are allowed)
Systemic (oral/intravenous [IV]/intramuscular [IM]) corticosteroids; patients on chronic stable dose of steroids at an equivalent dose of prednisone ? 10 mg daily may be permitted to enroll at the discretion of principal investigator
Receiving immunosuppressive agents or > 10 mg daily prednisone or equivalent of corticosteroids
Prior treatment with small molecule BET family inhibitor or receiving steroids >the equivalent of 10mg prednisone daily
Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily
Daily requirement for corticosteroids (> 10 mg prednisone daily or equivalent) (except for inhalation corticosteroids) within 2 weeks prior to Cycle 1, Day 1
Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed; patients may be using topical or inhaled corticosteroids
Need for daily corticosteroids at high doses (prednisone >= 20 mg daily, or an equivalent) is prohibited from 28 days prior to first dose and during treatment with ibrutinib; brief (up to 7 days) and episodic use of systemic corticosteroids for other general conditions (e.g. pre-medication for radiographic imaging due to intravenous [IV] contrast allergy, chronic obstructive pulmonary disease [COPD] exacerbation, poison ivy, etc.) is allowed
Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily
At least 2 weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except for =< 10 mg daily prednisone or equivalent which is permitted during the study)
Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
Concurrent steroids allowed (up to equivalent of prednisone 20 mg daily, on taper or stable dose for at least 2 weeks)
Systemic corticosteroids at doses greater than 40mg hydrocortisone daily or equivalent for any reason other than treatment of prostate cancer (PCa) within the previous 6 months
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810
Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to <= 10 mg prednisone daily).
Daily requirement for corticosteroids ? prednisone 10 mg/day or equivalent.
Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids), or any other immunosuppressive drugs.
No corticosteroids, or on a stable or decreasing dose of ? 10 mg daily prednisone (or equivalent)
Patients requiring daily corticosteroids at a prednisone equivalent of >= 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first dose
At least 4 weeks from last dose of therapeutic glucocorticosteroids. Adrenal replacement doses of glucocorticosteroids (up to the equivalent of 10 mg daily prednisone) are allowed.
Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against AITL, within the two weeks prior to treatment start. Concurrent corticosteroids are allowed, provided they are administered at an equivalent prednisone dose of ? 10 mg daily, as premedication for blood products only.
Current or recent (within 10 days prior to the first study drug dose) chronic daily treatment with aspirin (> 325 mg/day)
Chronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of randomization
Systemic steroids are allowed as long as they are tapered to the equivalent of 20 milligrams (mg) prednisone daily or less by the start of cycle 2
For phase I, prior intolerance to imatinib at a dose of 400 mg daily
Participants receiving daily treatment with aspirin >325mg/day or other known inhibitors of platelet function.
Patients must not require more than 20 mg prednisone or equivalent corticosteroid daily
Treatment with oral or parenteral corticosteroids dosed greater than 40 mg hydrocortisone daily or its equivalent (e.g., prednisone 10 mg, prednisolone 8 mg, or decadron 3 mg) =< 2 weeks of treatment initiation; or a clinical requirement for ongoing systemic immunosuppressive therapy
Subjects requiring daily corticosteroids at a prednisone equivalent of > 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day or prednisone equivalent), the discontinuation or dose reduction should be done at least 7 days prior to the first dose
Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone or equivalent [excluding inhaled steroids])
Use of a systemic steroid (> 5 mg prednisone daily or equivalent) =< 4 weeks prior to registration
Physiologic doses of corticosteroids are allowed (i.e. no more than 10 mg prednisone daily)
PHASE I: Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily
PHASE II: Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily
Current chronic daily treatment (continuous for > 3 months) with corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids
Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).
Short-course corticosteroids are permissible in the following circumstances:\r\n* Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (< 10 days) must have been discontinued prior to study treatment\r\n* Ongoing administration of a stable dose of corticosteroid therapy (equivalent to < 30 mg prednisone daily and previously received for >= 30 days) is permissible provided there is evidence of measurable disease and there will be no increase in steroid dose during the clinical trial
Patients requiring daily corticosteroids at a prednisone equivalent of >= 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first dose
Patients requiring daily corticosteroids at a prednisone equivalent of > 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day of prednisone or equivalent), the discontinuation or dose reduction should be done at least 7 days prior to first dose
Requirement for steroid use greater than 10 mg of prednisone daily
Treatment including chemotherapy, chemoimmunotherapy, monoclonal antibody therapy, radiotherapy, high-dose corticosteroid therapy (prednisone >= 60 mg daily, or equivalent), or immunotherapy within 3 weeks prior to enrollment or concurrent with this trial
No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.
Is taking chronic systemic steroids (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study treatment
High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomization
Subjects who will be or are currently being treated with high dose estrogen (high dose is defined as >0.625mg daily as conjugated estrogens or equivalent) within 7 days prior to study enrollment
Discontinuation of any glucocorticoids prescribed to specifically treat prostate cancer (e.g., as a secondary hormonal manipulation) > 4 weeks prior to receiving first dose of study drug. Glucocorticoids prescribed for a chronic non-cancer-related illness (e.g., asthma or COPD) that is well controlled with medical management are permissible to an equivalent of ? 10 mg prednisone daily.
Systemic treatment with high dose corticosteroids (greater than Prednisone 10mg daily or equivalent).
Minimal immunosuppression (defined as monotherapy with =< 10 mg prednisone daily, =< 200 mg cyclosporine daily, or =< 2 mg tacrolimus daily) at least 2 weeks prior to scheduled treatment
Active treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisone
Corticosteroid doses greater than equivalent of prednisone 7.5 mg orally (PO) daily
Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily.
Active treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisone
Individuals on a stable ruxolitinib dose of 5 mg once daily
Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily
Chronic daily treatment with corticosteroids (dose > 10 mg/day methylprednisolone equivalent) excluding inhaled steroids
Active treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisone
Active treatment with an oral or IV glucocortocoid for ?4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisone
Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent ? 5 mg prednisone or equivalent daily.
Most recent enzalutamide dose received is 160 mg once daily with no change in dose for at least 2 weeks prior to Screening.
Chronic corticosteroid use equivalent to >= prednisone 10 mg daily
Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate, or extracorporeal photopheresis
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810
Current chronic daily treatment with corticosteroids (>/= 10 mg/day methylprednisolone or equivalent), excluding inhaled steroids
Ongoing corticosteroid use with > 10 mg of daily prednisone or equivalent
Receiving chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet function
Use of corticosteroids as defined by a daily dose of prednisone (or equivalent) of 5 mg or greater for more than 1 month continuously within 3 months of screening
Treatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers are allowed.
Pre-existing condition that warrants long-term corticosteroid use greater than the equivalent of 10 mg prednisone daily; physiologic replacement is permitted; topical, intra-articular steroids or inhaled corticosteroids are permitted
Pre-existing opioid daily use of > 60mg morphine sulfate equivalent for reasons not related to LAHNC.
High dose steroid therapy (defined as > 5 mg prednisone, or equivalent, daily)
Chronic opioid use as defined by use of more than 20 mg oxycodone, or equivalent, daily
Known history of chronic pain disorders and/or chronic opioid use defined as > 10 mg of oral (PO) morphine or equivalent used daily for at least 30 days prior to enrollment
On strong opioids with morphine equivalent daily dose of 80-500 mg for at least one week, with stable (i.e. +/- 30%) regular dose over the last 24 hours
Chronic daily opioid requirement
On strong opioid intravenous continuous infusion morphine equivalent daily dose (MEDD) >= 70 mg/day at the time of enrollment
Is receiving high dose corticosteroids (>10 mg prednisone daily or equivalent);
On strong opioids with morphine equivalent daily dose of 60-130 mg for at least one week, with stable (i.e. +/- 30%) regular dose over the last 24 hours
On strong opioids with morphine equivalent daily dose of 80-500 mg, with stable (i.e. +/- 30%) regular dose over the last 24 hours
Patients with a history of severe chronic pain on high dose narcotics (> 25 mg of oxycodone or equivalent daily) preceding diagnosis of cancer
Current daily use of aspirin (> 81 mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen > 800 mg daily or equivalent)
Daily use of Facebook
Treatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers are allowed.
